1μg (R: reducing condition, N: non-reducing condition).
MMP-9 His Tag Protein, Cynomolgus
MMP-9 His Tag Protein, Cynomolgus
Price:
Regular price
$300.00 USD
Regular price
Sale price
$300.00 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Cynomolgus |
| Synonyms | Type V Collagenase，Gelatinase B，EC 3.4.24.35，MANDP2，Matrix Metalloproteinase 9，CLG4B，MMP9，Matrix Metallopeptidase 9，Matrix Metalloproteinase 9 (Gelatinase B， 92kDa Gelatinase， 92kDa Type IV Collagenase)，GELB，Matrix Metalloproteinase-9，92 KDa Type IV Collagenase，Macrophage Gelatinase，92 kDa gelatinase，MMP-9，Matrix Metallopeptidase 9 (Gelatinase B， 92kDa Gelatinase， 92kDa Type IV Collagenase)，EC:3.4.24.35，EC 3.4.24 |
| Accession | XP_005569271.2 |
| Amino Acid Sequence | Ala20-Asp707 with His Tag at C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 80-95kDa (Reducing) |
| Purity | > 95 % as determined by SDS-PAGE & SEC-HPLC |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, PH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | 1.St-Pierre Y, et al. (2003) Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr Drug Targets Inflamm Allergy. 2(3): 206-15. |
Background
Matrix metalloproteinases (MMPs) are neutral proteases involved in extracellular matrix (ECM) breakdown and remodeling during physiological processes like morphogenesis, angiogenesis, and tissue repair, as well as in pathological conditions such as inflammation, arthritis, and cancer. MMP9, or 92-kDa gelatinase B/type IV collagenase, is secreted by neutrophils, macrophages, and transformed cells. It is critical for tissue remodeling in inflammatory processes and is a key product of macrophages and neutrophils. MMP9 is also released by lymphocytes and stromal cells in response to inflammatory cytokines or integrin-mediated signals. Excessive MMP9 production is linked to tissue damage and degenerative disorders, making its regulation a focus for therapeutic development. Its overexpression in cancer and inflammatory conditions highlights the importance of understanding the mechanisms controlling its expression to identify potential therapeutic targets.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of MMP-9 His Tag Protein, Cynomolgus is greater than 95% as determined by SEC-HPLC.
ELISA
Immobilized MMP-9 His Tag Protein, Cynomolgus (Cat. No. UA011191) at 2.0μg/mL (100μL/well) can bind MMP9 Recombinant Rabbit mAb (SDT-368-16) (Cat. No. S0B2297) with EC50 of 0.95-1.73ng/mL.
